MAIA Biotechnology, Inc. (MAIA)
| Market Cap | 52.79M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -16.17M |
| Shares Out | 32.99M |
| EPS (ttm) | -0.60 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,622,467 |
| Open | 1.690 |
| Previous Close | 1.570 |
| Day's Range | 1.580 - 1.730 |
| 52-Week Range | 1.400 - 3.742 |
| Beta | 0.03 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 11, 2025 |
About MAIA
MAIA Biotechnology, Inc., together with its subsidiaries, immuno-oncology company, focuses on the development and commercialization of drugs with novel mechanisms of action that are intended to improve and extend the lives of people with cancer. Its lead program is THIO, a potential cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells. The company was incorporated in 2018 and is headquartered in Chicago, Illinois. [Read more]
Financial Performance
Financial StatementsNews
MAIA Biotechnology Receives FDA's Fast Track Designation for Ateganosine as a Treatment for Non-Small Cell Lung Cancer
CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Receives FDA's Fast Track Designation for Ateganosine as a Treatment for Non-Small Cell Lung Cancer.
MAIA Biotechnology Announces Peer-Reviewed Journal Publication of Data Validating Second Generation Ateganosine Prodrugs for Anticancer Therapy
CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Announces Peer-Reviewed Journal Publication of Data Validating Second Generation Ateganosine Prodrugs for Anticancer Therapy.
MAIA Biotechnology Announces First Patient Dosed in Expansion of Phase 2 Trial for Ateganosine in Advanced Non-Small Cell Lung Cancer
CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Announces First Patient Dosed in Expansion of Phase 2 Trial for Ateganosine in Advanced Non-Small Cell Lung Cancer.
MAIA Biotechnology to Present Two Posters Featuring Cancer Telomere-Targeting Agents at FEBS 2025 Congress
CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology to Present Two Posters Featuring Cancer Telomere-Targeting Agents at FEBS 2025 Congress.
MAIA Biotechnology Welcomes Leading Hepatocellular Carcinoma Clinician-Scientists to Scientific Advisory Board
CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Welcomes Leading Hepatocellular Carcinoma Clinician-Scientists to Scientific Advisory Board.
MAIA Biotechnology Announces Master Clinical Supply Agreement with Roche for Hard-to-Treat Cancer Therapies
CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Announces Master Clinical Supply Agreement with Roche for Hard-to-Treat Cancer Therapies.
MAIA Biotechnology to Present at BIO International Convention 2025
CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology to Present at BIO International Convention 2025.
MAIA Biotechnology's Experimental Cancer Drug Shows Tripled Survival Vs. Standard Chemotherapy In Pretreated Lung Cancer Patients
MAIA Biotechnology, Inc. MAIA on Thursday revealed updated data from its THIO-101 pivotal Phase 2 clinical trial.
MAIA Biotechnology Announces New Responder in Non-Small Cell Lung Cancer Phase 2 Clinical Trial
CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Announces New Responder in Non-Small Cell Lung Cancer Phase 2 Clinical Trial.
MAIA Biotechnology Announces Positive Efficacy Update for Phase 2 THIO-101 Clinical Trial in Non-Small Cell Lung Cancer
CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Announces Positive Efficacy Update for Phase 2 THIO-101 Clinical Trial in Non-Small Cell Lung Cancer.
CORRECTING and REPLACING MAIA Biotechnology Announces Private Placement of Approximately $695,000
CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Announces Private Placement of Approximately $695,000.
MAIA Biotechnology Announces Private Placement of Approximately $669,500
CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Announces Private Placement of Approximately $669,500.
MAIA Biotechnology Accepted for Poster Presentation at American Society of Clinical Oncology (ASCO) 2025 Annual Meeting
CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Accepted for Poster Presentation at American Society of Clinical Oncology (ASCO) 2025 Annual Meeting.
MAIA Biotechnology Announces Director Participation in Recent Private Placement
CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Announces Director Participation in Recent Private Placement.
CORRECTION: MAIA Biotechnology Announces $1.08 Million Private Placement
CHICAGO--(BUSINESS WIRE)--CORRECTION: MAIA Biotechnology Announces $1.08 Million Private Placement.
MAIA Biotechnology Announces $1.08 Million Private Placement
CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Announces $1.08 Million Private Placement.
MAIA Biotechnology CEO Details Anticipated Clinical Milestones for Novel Cancer Immunotherapy in 2025 Letter to Shareholders
CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology CEO Details Anticipated Clinical Milestones for Novel Cancer Immunotherapy in 2025 Letter to Shareholders.
MAIA Biotechnology Announces Poster Presentation at ESMO's European Lung Cancer Congress 2025
CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Announces Poster Presentation at ESMO's European Lung Cancer Congress 2025.
MAIA Biotechnology Announces Publication of Peer-Reviewed Study Featuring Potency and Potential of Novel THIO Prodrug
CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Announces Publication of Peer-Reviewed Study Featuring Potency and Potential of Novel THIO Prodrug.
MAIA Biotechnology Receives USAN Council Approval for “Ateganosine” as Nonproprietary Name for Anticancer Agent THIO
CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Receives USAN Council Approval for “Ateganosine” as Nonproprietary Name for Anticancer Agent THIO.
MAIA Biotechnology to Initiate Phase 3 Pivotal Trial of THIO Sequenced with Checkpoint Inhibitor Compared with Chemotherapy Treatment in Advanced Non-Small Cell Lung Cancer Patients
CHICAGO--(BUSINESS WIRE)--MAIA to Initiate Phase 3 Pivotal Trial of THIO Sequenced with Checkpoint Inhibitor Compared with Chemotherapy Treatment in Advanced NSCLC Patients.
MAIA Biotechnology Announces Design for Expansion of THIO-101 Phase 2 Trial in Advanced Non-Small Cell Lung Cancer
CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA,” the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today anno...
MAIA Biotechnology Announces Non-Brokered Private Placement of Approximately $1.43 Million
CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Announces Non-Brokered Private Placement of Approximately $1.43 Million.
MAIA Biotechnology Announces Private Placement of $2,715,000
CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Announces Private Placement of $2,715,000.
MAIA Biotechnology Announces Positive Efficacy Updates for Phase 2 THIO-101 Trial in Advanced Non-Small Cell Lung Cancer
CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Announces Positive Efficacy Updates for Phase 2 THIO-101 Trial in Advanced Non-Small Cell Lung Cancer.